A Green one-pot three component synthesis of thiazolidine-2,4-dione based bisspirooxindolo-pyrrolidines with [Bmim]BF4: their in vitro and in silico anti-TB studies
- PMID: 38789853
- DOI: 10.1007/s11030-024-10853-5
A Green one-pot three component synthesis of thiazolidine-2,4-dione based bisspirooxindolo-pyrrolidines with [Bmim]BF4: their in vitro and in silico anti-TB studies
Abstract
A simple and effective three-component one-pot green methodology was employed for the synthesis of a new thiazolidine-2,4-dione based bisspirooxindolo-pyrrolidine derivatives using [Bmim]BF4 ionic liquid via [3 + 2] cycloaddition reaction. It is an environmentally benign, column chromatography-free, shorter reaction time, good yield and easy product isolation method. The synthesized compounds 10a-x, were thoroughly characterized by using various spectroscopic methods like FT-IR, 1H NMR, 13C NMR, Mass spectrometry and finally by single crystal X-ray diffraction method. In vitro anti-tubercular (anti-TB) activity studies were carried out on these synthesized compounds, and they showed good to moderate anti-TB activity against Mycobacterium tuberculosis H37Rv strain. The compound 10a exhibited good anti-TB activity, with an MIC (Minimum Inhibitory Concentration) value of 12.5 µg/mL, and the compounds 10m, 10o and 10r showed moderate activity with an MIC value of 25.0 µg/mL. Remaining compounds exhibited poor activity against Mycobacterium tuberculosis. Ethambutol, rifampicin and isoniazid were used as standard drugs. Furthermore, in silico molecular docking experiments on the TB protein (PDB ID: 1DF7) were carried out to understand the binding interactions, and they showed least binding energy values ranging from -8.9 to -7.2 kcal/mol.
Keywords: Anti-TB activity; Green synthesis; Molecular docking; Thiazolidine-2,4-dione based bisspirooxindolo-pyrrolidines; [3 + 2] cycloaddition reaction; [Bmim]BF4.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.Med Chem. 2019;15(3):311-326. doi: 10.2174/1573406414666180703121815. Med Chem. 2019. PMID: 29968540
-
Chroman-Schiff base derivatives as potential Anti-Tubercular Agents: In silico studies, Synthesis, and Biological evaluation.Bioorg Chem. 2025 Apr;157:108249. doi: 10.1016/j.bioorg.2025.108249. Epub 2025 Feb 7. Bioorg Chem. 2025. PMID: 39965447
-
Design, synthesis, anti-mycobacterial activity, molecular docking and ADME analysis of spiroquinoxaline-1,2,4-oxadiazoles via [3 + 2] cycloaddition reaction under ultrasound irradiation.Mol Divers. 2024 Dec;28(6):3979-3991. doi: 10.1007/s11030-023-10790-9. Epub 2024 Jan 23. Mol Divers. 2024. PMID: 38261121
-
The new thiazolidine-2,4-dione-based hybrids with promising antimycobacterial activity: design, synthesis, biological evaluation, and drug interaction analysis.J Enzyme Inhib Med Chem. 2025 Dec;40(1):2442703. doi: 10.1080/14756366.2024.2442703. Epub 2025 Jan 3. J Enzyme Inhib Med Chem. 2025. PMID: 39749402 Free PMC article.
-
Synthesis of New 3-Arylaminophthalides and 3-Indolyl-phthalides using Ammonium Chloride, Evaluation of their Anti-Mycobacterial Potential and Docking Study.Comb Chem High Throughput Screen. 2020;23(8):723-739. doi: 10.2174/1386207323666200422082754. Comb Chem High Throughput Screen. 2020. PMID: 32321396 Review.
References
-
- World Health Organization (2023) Global tuberculosis report 2023. World Health Organization, Geneva ( https://www.who.int/publications/i/item/9789240083851 )
-
- Komakech K, Nakiyingi L, Fred A, Achan B, Joloba M, Kirenga BJ, Ssengooba W (2024) Effect of mixed mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in uganda. BMC Infect Dis 24:1–8. https://doi.org/10.1186/s12879-023-08968-5 - DOI
-
- Bhowruth V, Dover LG, Besra GS (2007) 4 tuberculosis chemotherapy: recent developments and future perspectives. Prog Med Chem 45:169–203. https://doi.org/10.1016/S0079-6468(06)45504-1 - DOI - PubMed
-
- Preez ID, Loots DT (2018) Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance. Drug Metab Rev 50:466–481. https://doi.org/10.1080/03602532.2018.1559184 - DOI - PubMed
-
- Molla Y, Wubetu M, Dessie B (2021) Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, ethiopia. Hepatic Med Evid Res 13:1–8. https://doi.org/10.2147/hmer.s290542 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous